TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
PLANO, Texas, April 27, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended March 31, 2017 on Tuesday, May 9, 2017 after market close.
Nuvectra will hold a conference call on Tuesday, May 9, 2017 at 4:30pm ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID is 9040428. A live webcast of the conference call will be available on the investor relations section of the Company’s website at http://investors.nuvectramed.com/.
A replay of the call will be available starting on May 9, 2017 through May 16, 2017. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 9040428. The webcast will be available in the investor relations section of the Company’s website for 90 days following the completion of the call.
About Nuvectra Corporation
NuvectraTM is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Operating Officer and Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
